Goxalapladib is a small-molecule phospholipase A2 inhibitor with the molecular formula C40H39F5N4O3 and CAS number 412950-27-7. Developed initially by GSK, its development status is discontinued. The USAN statement lists it for potential treatment of atherosclerosis. Its therapeutic use is listed as cardiovascular. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include goxalapladibum. Its PubChem CID is 11686305.
Goxalapladib
| CAS No | 412950-27-7 |
|---|---|
| Molecular Formula | C40H39F5N4O3 |
| Molecular Weight | 718.8 g/mol |
| Synonyms | 2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Goxalapladib is a small-molecule phospholipase A2 inhibitor with the molecular formula C40H39F5N4O3 and CAS number 412950-27-7. Developed initially by GSK, its development status is discontinued.
The listed CAS number is 412950-27-7.
The listed molecular formula is C40H39F5N4O3.
The listed molecular weight is 718.8 g/mol.
2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide.
The source lists goxalapladibum.